Navigation Links
Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
Date:12/1/2009

CRANBURY, N.J., Dec. 1 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,622,440, titled "Cyclic Natriuretic Peptide Constructs." The claims in the issued patent cover a family of cyclic compounds that bind to natriuretic peptide receptor A (NPRA), including PL-3994, Palatin's lead heart failure drug candidate.

"Our natriuretic compounds, including PL-3994, address significant unmet medical needs," said Trevor Hallam, Ph.D., Palatin's Executive Vice President - Research and Development. "These are the only reported compounds that bind to NPRA and have extended half-lives and pharmacokinetic properties making daily subcutaneous administration possible. Besides the potential to decrease re-hospitalization rates in patients with heart failure, PL-3994 may also have application in treating resistant hypertension and pulmonary arterial hypertension."

PL-3994 and the related family of cyclic compounds were discovered and developed by Palatin scientists and are solely owned by Palatin. In addition to this issued U.S. patent, Palatin has applications pending in selected countries outside the United States and additional U.S. applications covering related compounds.

About PL-3994

Palatin has completed two clinical trials with PL-3994, a Phase 1 trial in healthy volunteers and a Phase 2a trial in patients with controlled hypertension. PL-3994 produced dose-related decreases in blood pressure, increases in plasma cGMP (cyclic guanosine monophosphate), a natural messenger nucleotide, and increases in urine volume and sodium excretion. There were no serious or severe adverse events.

PL-3994 incorporates a novel and proprietary amino acid mimetic developed by scientists at Palatin
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
2. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
3. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
4. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
5. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
6. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
9. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
10. Palatin Technologies Receives Notification Letter from NYSE Alternext US
11. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RedBrick Health , a fast-growing leader in consumer health ... EmblemHealth , the New York -based ... RedBrick Compass health assessment, combined with the RedBrick Journeys ... EmblemHealth is among the first health plans in the ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up their ... of them wrote: "Take better care of my furry companion." Nowadays ... clothes and top-brand carrying cases to take the little canine or ... also feel compelled to buy some pricey toys at the pet ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... Sequenom, Inc. (NASDAQ: SQNM ), a ... announced the acceptance for publication of the manuscript, "Clinical ... of Developing Choroidal Neovascular Age-related Macular Degeneration." The article ... Genomics . The study, conducted by the company,s wholly-owned ...
... who design new materials often struggle to understand ... including polymers and biological materials change upon cooling ... a tar-like consistency at intermediate temperatures, then become ... lower temperatures. Scientists have long sought a molecular-level ...
... Researchers at Northwestern University have created a new ... invisible in the terahertz range. Though this ... the visible spectrum, it could have implications in ... by Cheng Sun, assistant professor of mechanical engineering ...
Cached Biology Technology:Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study 2Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study 3Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study 4Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study 5Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study 6Understanding how glasses 'relax' provides some relief for manufacturers 2Researchers create terahertz invisibility cloak 2
(Date:7/9/2014)... nature,s ability to split the water molecule during ... artificial photosynthesis for clean, green and renewable energy ... scientists led by researchers with the Lawrence Berkeley ... Accelerator Laboratory. , Working at SLAC,s Linac ... x-ray laser, the researchers were able to take ...
(Date:7/9/2014)... about the prevalence of antibiotic-resistant illness, Case Western ... to disabling disease: blocking bacteria,s access to iron ... bacterial siderophore, a small molecule, captures iron from ... as well as how the body launches ... findings appear in a recent edition of ...
(Date:7/9/2014)... first-ever global census of Adlie penguins shows that ... 53 percent larger than previously estimated. Adlie penguins ... to monitor and understand the effects of climate ... By using high-resolution satellite imagery, researchers from Stony ... a new method that permits regular monitoring of ...
Breaking Biology News(10 mins):Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Bacteria hijack plentiful iron supply source to flourish 2New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3
... researchers report that common assumptions employed in the generation ... can lead to seriously flawed conclusions about gene activity ... biological research. "Expression analysis is one of the ... Member Richard Young. "So we are concerned that flawed ...
... new collaborative project among researchers from Uppsala University in ... first time, demonstrated experimentally the evolutionary force behind the ... of seed beetle. This mechanism is revealed ... Current Biology . The experiments leading to this ...
... PITTSBURGHWhile Omega-3 essential fatty acidsfound in foods like wild ... their effects on the working memory of healthy young ... the first study of its kind, researchers at the ... ages 18-25 can improve their working memory even further ...
Cached Biology News:Whitehead scientists identify major flaw in standard approach to global gene expression analysis 2Size does matter in sexual selection, at least among beetles 2Omega-3 intake heightens working memory in healthy young adults 2Omega-3 intake heightens working memory in healthy young adults 3
Adhesion Molecule Antibodies...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Anti-Mouse IgM Heavy Chain:FITC, Clone LO-MM-9, Monoclonal Antibody...
Biology Products: